Eli Lilly and Co. has announced plans to spend more than $6 billion on a new manufacturing plant in Huntsville, Alabama, that will produce small-molecule and peptide drugs, including the company’s highly anticipated GLP-1 oral medication, orforglipron.... Read More
Eli Lilly and Co. and Indiana University have announced a new agreement that would see the company to provide up to $40 million over five years to the university to bolster clinical trials and enhance care and research focused on Alzheimer’s disease.... Read More
St. Louis-based nonprofit health system Ascension on Monday named Don King as its CEO for Ascension St. Vincent in Indiana, where he will oversee a network comprising more than 15,000 employees at 19 hospitals and more than 300 sites of care.... Read More
Officials from the Indianapolis-based health care system are preparing for a sharp, yearslong rise in energy use at their $4.3 billion hospital expected to open in late 2027, much higher than power needs at their current Methodist and University hospitals.... Read More
The Indianapolis drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers and others covered by their health plans.... Read More
Encompass Health Corp. plans to build a freestanding 50-bed rehabilitation hospital in Fishers, the Birmingham, Alabama-based company announced Monday.... Read More
Butler University on Thursday announced Dr. Michael Hole, a Stanford University-educated physician and U.S. Air Force Reserve officer who grew up in rural Indiana, as its next executive vice president and provost.... Read More
Eli Lilly and Co. said Wednesday it plans to open a new Lilly Gateway Labs site in Philadelphia, part of a broader effort to help foster biotech startups and innovations.... Read More
Franciscan Health Indianapolis this week announced plans to build a new $60 million, 40-bed inpatient rehabilitation hospital on its south-side campus to accommodate patients recovering from strokes, cardiac events, brain injuries and other medical issues.... Read More
The clinical trial, announced last month, focuses on Beverly, Massachusetts-based Akston Bioscience Corp.’s Ambifect immune-enhancing therapy, with Purdue researchers looking to enroll about 10 dogs.... Read More
